作者:James F. Blake、Nicholas C. Kallan、Dengming Xiao、Rui Xu、Josef R. Bencsik、Nicholas J. Skelton、Keith L. Spencer、Ian S. Mitchell、Richard D. Woessner、Susan L. Gloor、Tyler Risom、Stefan D. Gross、Matthew Martinson、Tony H. Morales、Guy P.A. Vigers、Barbara J. Brandhuber
DOI:10.1016/j.bmcl.2010.08.053
日期:2010.10
The discovery and optimization of a series of pyrrolopyrimidine based protein kinase B (Pkb/Akt) inhibitors discovered via HTS and structure based drug design is reported. The compounds demonstrate potent inhibition of all three Akt isoforms and knockdown of phospho-PRAS40 levels in LNCaP cells and tumor xenografts. (C) 2010 Elsevier Ltd. All rights reserved.